{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T17:32:33Z","timestamp":1795109553812,"version":"4.10.3"},"reference-count":33,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,2,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Cold agglutinin disease is a difficult-to-treat autoimmune hemolytic anemia in which immunoglobulin M antibodies bind to erythrocytes and fix complement, resulting in predominantly extravascular hemolysis. This trial tested the hypothesis that the anti-C1s antibody sutimlimab would ameliorate hemolytic anemia. Ten patients with cold agglutinin disease participated in the phase 1b component of a first-in-human trial. Patients received a test dose of 10-mg\/kg sutimlimab followed by a full dose of 60 mg\/kg 1 to 4 days later and 3 additional weekly doses of 60 mg\/kg. All infusions were well tolerated without premedication. No drug-related serious adverse events were observed. Seven of 10 patients with cold agglutinin disease responded with a hemoglobin increase &amp;gt;2 g\/dL. Sutimlimab rapidly increased hemoglobin levels by a median of 1.6 g\/dL within the first week, and by a median of 3.9 g\/dL (interquartile range, 1.3-4.5 g\/dL; 95% confidence interval, 2.1-4.5) within 6 weeks (P = .005). Sutimlimab rapidly abrogated extravascular hemolysis, normalizing bilirubin levels within 24 hours in most patients and normalizing haptoglobin levels in 4 patients within 1 week. Hemolytic anemia recurred when drug levels were cleared from the circulation 3 to 4 weeks after the last dose of sutimlimab. Reexposure to sutimlimab in a named patient program recapitulated the control of hemolytic anemia. All 6 previously transfused patients became transfusion-free during treatment. Sutimlimab was safe, well tolerated, and rapidly stopped C1s complement\u2013mediated hemolysis in patients with cold agglutinin disease, significantly increasing hemoglobin levels and precluding the need for transfusions. This trial was registered at www.clinicaltrials.gov as #NCT02502903.<\/jats:p>","DOI":"10.1182\/blood-2018-06-856930","type":"journal-article","created":{"date-parts":[[2018,12,17]],"date-time":"2018-12-17T15:05:12Z","timestamp":1545059112000},"page":"893-901","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":108,"title":["Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial"],"prefix":"10.1182","volume":"133","author":[{"given":"Ulrich","family":"J\u00e4ger","sequence":"first","affiliation":[{"name":"Division of Haematology, Department of Internal Medicine, Medical University of Vienna, Vienna, Austria;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirley","family":"D\u2019Sa","sequence":"additional","affiliation":[{"name":"Waldenstr\u00f6ms, POEMS and Myeloma Clinics, University College London Hospitals, National Health Service Foundation Trust & Mount Vernon Cancer Centre, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2286-1077","authenticated-orcid":false,"given":"Christian","family":"Sch\u00f6rgenhofer","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"Bartko","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulla","family":"Derhaschnig","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Sillaber","sequence":"additional","affiliation":[{"name":"Division of Haematology, Department of Internal Medicine, Medical University of Vienna, Vienna, Austria;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Jilma-Stohlawetz","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Fillitz","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hanusch Krankenhaus, Vienna, Austria;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Schenk","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Universit\u00e4tsklinikum St. P\u00f6lten, St. P\u00f6lten, Austria;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Patou","sequence":"additional","affiliation":[{"name":"Bioverativ, a Sanofi company, Waltham, MA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7901-2730","authenticated-orcid":false,"given":"Sandip","family":"Panicker","sequence":"additional","affiliation":[{"name":"Bioverativ, a Sanofi company, Waltham, MA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham C.","family":"Parry","sequence":"additional","affiliation":[{"name":"Bioverativ, a Sanofi company, Waltham, MA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James C.","family":"Gilbert","sequence":"additional","affiliation":[{"name":"Band Therapeutics, LLC, Belmont, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5652-7977","authenticated-orcid":false,"given":"Bernd","family":"Jilma","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021109072767900_B1","first-page":"648","article-title":"Autoimmune hemolytic anemia","volume-title":"Hematology 7th Edition. Basic Principles and Practice","author":"Michel","year":"2017"},{"issue":"10","key":"2020021109072767900_B2","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1056\/NEJM197709082971005","article-title":"Biologic activity of cold-reacting autoantibodies (first of two parts)","volume":"297","author":"Pruzanski","year":"1977","journal-title":"N Engl J Med"},{"issue":"10","key":"2020021109072767900_B3","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.3324\/haematol.2014.114561","article-title":"Treatment of autoimmune hemolytic anemias","volume":"99","author":"Zanella","year":"2014","journal-title":"Haematologica"},{"key":"2020021109072767900_B4","doi-asserted-by":"crossref","first-page":"363278","DOI":"10.1155\/2015\/363278","article-title":"Red blood cell destruction in autoimmune hemolytic anemia: role of complement and potential new targets for therapy","volume":"2015","author":"Berentsen","year":"2015","journal-title":"BioMed Res Int"},{"issue":"4","key":"2020021109072767900_B5","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.blre.2017.02.003","article-title":"Complementopathies","volume":"31","author":"Baines","year":"2017","journal-title":"Blood Rev"},{"issue":"5","key":"2020021109072767900_B6","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1159\/000438964","article-title":"Role of complement in autoimmune hemolytic anemia","volume":"42","author":"Berentsen","year":"2015","journal-title":"Transfus Med Hemother"},{"issue":"4","key":"2020021109072767900_B7","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1172\/JCI108547","article-title":"The role of complement in the clearance of cold agglutinin-sensitized erythrocytes in man","volume":"58","author":"Jaffe","year":"1976","journal-title":"J Clin Invest"},{"issue":"22","key":"2020021109072767900_B8","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1182\/blood-2015-06-640995","article-title":"Complement in hemolytic anemia","volume":"126","author":"Brodsky","year":"2015","journal-title":"Blood"},{"key":"2020021109072767900_B9","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1182\/asheducation-2016.1.226","article-title":"Cold agglutinin disease","volume":"2016","author":"Berentsen","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"5","key":"2020021109072767900_B10","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1586\/17474086.2015.1073105","article-title":"Current treatment strategies in autoimmune hemolytic disorders","volume":"8","author":"Barcellini","year":"2015","journal-title":"Expert Rev Hematol"},{"issue":"19","key":"2020021109072767900_B11","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1182\/bloodadvances.2018024190","article-title":"Eculizumab in cold agglutinin disease (DECADE): an open-label, prospective, bicentric, nonrandomized phase 2 trial","volume":"2","author":"R\u00f6th","year":"2018","journal-title":"Blood Adv"},{"issue":"26","key":"2020021109072767900_B12","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1182\/blood-2014-02-556027","article-title":"TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinins","volume":"123","author":"Shi","year":"2014","journal-title":"Blood"},{"issue":"9","key":"2020021109072767900_B13","doi-asserted-by":"crossref","first-page":"e361","DOI":"10.3324\/haematol.2016.146126","article-title":"Immunoglobulin heavy and light chain gene features are correlated with primary cold agglutinin disease onset and activity","volume":"101","author":"Ma\u0142ecka","year":"2016","journal-title":"Haematologica"},{"issue":"3","key":"2020021109072767900_B14","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3324\/haematol.2013.091702","article-title":"Primary cold agglutinin-associated lymphoproliferative disease: a B-cell lymphoma of the bone marrow distinct from lymphoplasmacytic lymphoma","volume":"99","author":"Randen","year":"2014","journal-title":"Haematologica"},{"issue":"7","key":"2020021109072767900_B15","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1182\/blood-2013-02-474437","article-title":"Cold agglutinin disease","volume":"122","author":"Swiecicki","year":"2013","journal-title":"Blood"},{"issue":"4","key":"2020021109072767900_B16","first-page":"460","article-title":"Primary chronic cold agglutinin disease: a population based clinical study of 86 patients","volume":"91","author":"Berentsen","year":"2006","journal-title":"Haematologica"},{"issue":"13","key":"2020021109072767900_B17","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1182\/bloodadvances.2017004390","article-title":"Cold agglutinin disease burden: a longitudinal analysis of anemia, medications, transfusions, and health care utilization","volume":"1","author":"Mullins","year":"2017","journal-title":"Blood Adv"},{"issue":"19","key":"2020021109072767900_B18","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1182\/blood-2014-06-583021","article-title":"Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients","volume":"124","author":"Barcellini","year":"2014","journal-title":"Blood"},{"issue":"4","key":"2020021109072767900_B19","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1053\/j.seminhematol.2015.05.001","article-title":"Immune hemolysis: diagnosis and treatment recommendations","volume":"52","author":"Barcellini","year":"2015","journal-title":"Semin Hematol"},{"issue":"8","key":"2020021109072767900_B20","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1182\/blood-2003-10-3597","article-title":"Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients","volume":"103","author":"Berentsen","year":"2004","journal-title":"Blood"},{"issue":"2","key":"2020021109072767900_B21","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/10428190500286481","article-title":"Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients","volume":"47","author":"Sch\u00f6llkopf","year":"2006","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2020021109072767900_B22","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1182\/blood-2017-04-778175","article-title":"Bendamustine plus rituximab for chronic cold agglutinin disease: results of a Nordic prospective multicenter trial","volume":"130","author":"Berentsen","year":"2017","journal-title":"Blood"},{"issue":"17","key":"2020021109072767900_B23","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1182\/blood-2010-06-288647","article-title":"High response rate and durable remissions following fludarabine and rituximab combination therapy for chronic cold agglutinin disease","volume":"116","author":"Berentsen","year":"2010","journal-title":"Blood"},{"issue":"6","key":"2020021109072767900_B24","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1080\/10428190701385173","article-title":"Autoimmune hemolytic anemias, Evans\u2019 syndromes, and pure red cell aplasia in non-Hodgkin lymphomas","volume":"48","author":"Hauswirth","year":"2007","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"2020021109072767900_B25","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1182\/blood-2010-03-259325","article-title":"How I treat autoimmune hemolytic anemias in adults","volume":"116","author":"Lechner","year":"2010","journal-title":"Blood"},{"issue":"1","key":"2020021109072767900_B26","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1186\/1752-1947-4-252","article-title":"Fatal cold agglutinin-induced haemolytic anaemia: a case report","volume":"4","author":"Lodi","year":"2010","journal-title":"J Med Case Reports"},{"issue":"6","key":"2020021109072767900_B27","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/00062752-200311000-00006","article-title":"Red blood cell transfusion in autoimmune hemolytic anemia","volume":"10","author":"Buetens","year":"2003","journal-title":"Curr Opin Hematol"},{"issue":"1","key":"2020021109072767900_B28","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s13023-016-0494-z","article-title":"Combined integrated protocol\/basket trial design for a first-in-human trial","volume":"11","author":"Derhaschnig","year":"2016","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"2020021109072767900_B29","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/cpt.1111","article-title":"A randomized, first-in-human, healthy volunteer trial of sutimlimab, a humanized antibody for the specific inhibition of the classical complement pathway","volume":"104","author":"Bartko","year":"2018","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"2020021109072767900_B30","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1365-2249.1995.tb03480.x","article-title":"Low activity of the classical complement pathway predicts short survival of patients with chronic lymphocytic leukaemia","volume":"99","author":"Varga","year":"1995","journal-title":"Clin Exp Immunol"},{"issue":"23","key":"2020021109072767900_B31","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.274.274","article-title":"Complement inhibition with eculizumab in patients with cold agglutinin disease (CAD): results from a prospective phase II trial (DECADE Trial) [abstract]","volume":"126","author":"R\u00f6th","year":"2015","journal-title":"Blood"},{"issue":"4","key":"2020021109072767900_B32","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/ajt.14528","article-title":"Anti-C1s monoclonal antibody BIVV009 in late antibody-mediated kidney allograft rejection\u2014results from a first-in-patient phase 1 trial","volume":"18","author":"Eskandary","year":"2018","journal-title":"Am J Transplant"},{"issue":"1","key":"2020021109072767900_B33","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/s41598-017-17934-6","article-title":"Single, very low rituximab doses in healthy volunteers\u2014a pilot and a randomized trial: implications for dosing and biosimilarity testing","volume":"8","author":"Schoergenhofer","year":"2018","journal-title":"Sci Rep"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/133\/9\/893\/1558164\/blood856930.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/133\/9\/893\/1558164\/blood856930.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T09:40:06Z","timestamp":1581414006000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/133\/9\/893\/260641\/Inhibition-of-complement-C1s-improves-severe"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,28]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,2,28]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2018-06-856930","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,28]]}}}